Our Pipeline

Best-in-Class, Oral Drugs for Inflammatory and Metabolic Diseases

Project

Lead Optimization

Pre-Clinical

Phase 1

Phase 2

Phase 3

ABP-671

URAT1 inhibitor
(Lingolinurad)

Gout & Hyperuricemia

Chronic Kidney Disease

Refactory Gout

ABP-745

Acute Gout & Other Indications

ABP-6118

Xanthine Oxidase Inhibitor

Gout

ABP-431

Anticancer

Learn About ABP-671 for Chronic Gout

Learn About ABP-745 for Acute Gout